Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina, USA.
Institute of Biomedical Engineering, Boğaziçi University, Istanbul, Turkey.
Photochem Photobiol. 2024 Nov-Dec;100(6):1603-1621. doi: 10.1111/php.14014. Epub 2024 Aug 27.
Over 75% percent of ovarian cancer patients are diagnosed with advanced-stage disease characterized by unresectable intraperitoneal dissemination and the presence of ascites, or excessive fluid build-up within the abdomen. Conventional treatments include cytoreductive surgery followed by multi-line platinum and taxane chemotherapy regimens. Despite an initial response to treatment, over 75% of patients with advanced-stage ovarian cancer will relapse and succumb to platinum-resistant disease. Recent evidence suggests that fluid shear stress (FSS), which results from the movement of fluid such as ascites, induces epithelial-to-mesenchymal transition and confers resistance to carboplatin in ovarian cancer cells. This study demonstrates, for the first time, that FSS-induced platinum resistance correlates with increased cellular protoporphyrin IX (PpIX), the penultimate downstream product of heme biosynthesis, the production of which can be enhanced using the clinically approved pro-drug aminolevulinic acid (ALA). These data suggest that, with further investigation, PpIX could serve as a fluorescence-based biomarker of FSS-induced platinum resistance. Additionally, this study investigates the efficacy of PpIX-enabled photodynamic therapy (PDT) and the secretion of extracellular vesicles under static and FSS conditions in Caov-3 and NIH:OVCAR-3 cells, two representative cell lines for high-grade serous ovarian carcinoma (HGSOC), the most lethal form of the disease. FSS induces resistance to ALA-PpIX-mediated PDT, along with a significant increase in the number of EVs. Finally, the ability of PpIX-mediated photodynamic priming (PDP) to enhance carboplatin efficacy under FSS conditions is quantified. These preliminary findings in monolayer cultures necessitate additional studies to determine the feasibility of PpIX as a fluorescence-based indicator, and mediator of PDP, to target chemoresistance in the context of FSS.
超过 75%的卵巢癌患者被诊断为晚期疾病,其特征是不可切除的腹腔内播散和腹水存在,或腹腔内过多的液体积聚。传统的治疗方法包括细胞减灭术,然后是多线铂类和紫杉烷化疗方案。尽管对治疗有初步反应,但超过 75%的晚期卵巢癌患者会复发并死于铂类耐药疾病。最近的证据表明,流体切应力(FSS),这是由腹水等流体运动引起的,诱导上皮-间充质转化,并使卵巢癌细胞对卡铂产生耐药性。这项研究首次表明,FSS 诱导的铂类耐药性与细胞原卟啉 IX(PpIX)的增加相关,PpIX 是血红素生物合成的倒数第二个下游产物,其产生可以使用临床批准的前体药物氨基酮戊酸(ALA)来增强。这些数据表明,随着进一步的研究,PpIX 可以作为 FSS 诱导的铂类耐药性的荧光生物标志物。此外,本研究还研究了 PpIX 增强的光动力疗法(PDT)和在静态和 FSS 条件下在 Caov-3 和 NIH:OVCAR-3 细胞中细胞外囊泡分泌的功效,这两种细胞系是高级别浆液性卵巢癌(HGSOC)的代表细胞系,是该疾病最致命的形式。FSS 诱导对 ALA-PpIX 介导的 PDT 的耐药性,同时 EV 数量显著增加。最后,量化了 PpIX 介导的光动力预刺激(PDP)在 FSS 条件下增强卡铂疗效的能力。这些单层培养物中的初步发现需要进一步研究,以确定 PpIX 作为荧光生物标志物的可行性,以及作为 PDP 的介导物,以针对 FSS 背景下的化疗耐药性。